{'output': [['Taxus Cardium Pharmaceuticals Group', 'ORG', 'Announce', 'Gene Biotherapeutics', 'ORG'], ['Gene Biotherapeutics', 'ORG', 'Operate_In', 'Oncology and Cardiology spaces', 'SECTOR'], ['Gene Biotherapeutics', 'ORG', 'Produce', 'Gene-based biotherapeutics', 'PRODUCT'], ['Gene Biotherapeutics', 'ORG', 'Participates_In', 'Late-stage clinical research', 'CONCEPT'], ['Gene Biotherapeutics', 'ORG', 'Control', 'Adenovector-based technology platform', 'CONCEPT'], ['Angionetics Inc.', 'ORG', 'Is_Member_Of', 'Gene Biotherapeutics', 'ORG'], ['Angionetics Inc.', 'ORG', 'Operate_In', 'Cardiovascular clinical research and commercialization activities', 'CONCEPT'], ['Angionetics Inc.', 'ORG', 'Produce', 'Generx AFFIRM Phase 3 clinical study', 'EVENT'], ['Angionetics Inc.', 'ORG', 'Control', 'FDA-cleared Generx', 'PRODUCT'], ['Angionetics Inc.', 'ORG', 'Impact', 'Patients with refractory angina', 'CONCEPT'], ['Angionetics Inc.', 'ORG', 'Raise', 'Independent financings', 'CONCEPT'], ['Angionetics Inc.', 'ORG', 'Consider', 'Multiple Phase 2 clinical studies', 'EVENT'], ['Angionetics Inc.', 'ORG', 'Produce', 'Generx [Ad5FGF-4]', 'PRODUCT'], ['Generx [Ad5FGF-4]', 'PRODUCT', 'Impact', 'Enhance blood flow', 'CONCEPT'], ['Generx [Ad5FGF-4]', 'PRODUCT', 'Impact', 'Promote the natural formation and growth of microvascular coronary structures', 'CONCEPT'], ['Generx [Ad5FGF-4]', 'PRODUCT', 'Impact', 'Stimulating and augmenting the heart innate natural capacity to modulate the enlargement of pre-existing collateral arterioles', 'CONCEPT'], ['Generx [Ad5FGF-4]', 'PRODUCT', 'Impact', 'Form new capillary vessels in select ischemic regions downstream from large coronary arteries', 'CONCEPT'], ['Angionetics Inc.', 'ORG', 'Ambition', 'Develop a portfolio of new and innovative, single-treatment, gene-based, catheter-administered therapeutic products', 'CONCEPT'], ['Angionetics Inc.', 'ORG', 'Consider', 'Acquisition of several early-stage gene therapy product candidates', 'CONCEPT'], ['Gene Biotherapeutics', 'ORG', 'Plan', 'Monetize its FDA-cleared, U.S.-patented, Excellagen', 'PRODUCT'], ['Excellagen', 'PRODUCT', 'Designated', 'Skin substitute', 'CONCEPT'], ['Excellagen', 'PRODUCT', 'Carry', 'Potential as a topical dermal delivery vehicle for small molecule drugs, peptides, proteins, and exosomes', 'CONCEPT'], ['Gene Biotherapeutics', 'ORG', 'Issue', 'Gene Biotherapeutics Common Stock', 'FIN_INSTRUMENT'], ['Gene Biotherapeutics', 'ORG', 'Reserve', 'Future issuance upon the conversion of the Series A Convertible Preferred Stock', 'FIN_INSTRUMENT'], ['Gene Biotherapeutics', 'ORG', 'Cautionary', 'Forward-Looking Statements', 'CONCEPT'], ['Gene Biotherapeutics', 'ORG', 'Require', 'Raise significant capital', 'CONCEPT'], ['Gene Biotherapeutics', 'ORG', 'Plan', 'Commercialization of the product and product candidates described in this press release', 'CONCEPT']]}